The Patent Finder

Terms ending in 2030

CSL Behring GmbH

Every in-force patent on CSL Behring GmbH's record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 8,632,773Antibody Composition with Altered Fab Sialylation
In force
 · High confidence
CSL Behring AGIn forceHigh confidence
US 8,603,979Von Willebrand Factor or Factor VIII and Von Willebrand Factor for the Treatment of Coagulopathy Induced by Inhibitors of Thrombocytes
In force
 · High confidence
CSL Behring GmbHIn forceHigh confidence
US 7,939,632Proteolytically Cleavable Fusion Proteins with High Molar Specific Activity
In force
 · High confidence
CSL Behring GmbHIn forceHigh confidence
3 of 3 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited